MEI Pharma's gross profit for the
three
months ended in Dec. 2024 was $0.00 Mil. MEI Pharma's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. MEI Pharma's gross profit for the
three
months ended in Dec. 2024 was $0.00 Mil. MEI Pharma's Revenue for the
three
months ended in Dec. 2024 was $0.00 Mil. Therefore, MEI Pharma's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.
MEI Pharma had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of MEI Pharma was 95.95%. The lowest was -108.57%. And the median was 78.49%.
MEI Pharma Gross Profit Historical Data
The historical data trend for MEI Pharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of MEI Pharma's Gross Profit
For the Biotechnology subindustry, MEI Pharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MEI Pharma's Gross Profit Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MEI Pharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where MEI Pharma's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
MEI Pharma (NAS:MEIP) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
MEI Pharma had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage
MEI Pharma Gross Profit Related Terms
Thank you for viewing the detailed overview of MEI Pharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
MEI Pharma Inc is focused on the clinical development of novel therapies for cancer. The company's clinical drug candidate includes Pracinostat, an orally available histone deacetylase inhibitor for the treatment of patients with acute myeloid leukemia and myelodysplastic syndrome. Its clinical development portfolio also includes Zandelisib, an oral inhibitor of phosphatidylinositide 3-kinase delta for the treatment of patients with recurrent chronic lymphocytic leukemia or follicular non-Hodgkin's lymphoma; and ME-344, an isoflavone-based mitochondrial inhibitor for the treatment of HER2-negative breast cancer and Pracinostat, an oral histone deacetylase inhibitor. Geographically, all the business activities function through the region of the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
MEIP has been successfully added to your 